FT Options’s Alnylam Pharmaceuticals ALNY Stock Holding History

FT Options’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$2.1M	Buy	+101,100	New	+$8.63M	3.17%	4
2016 Q4	–	Sell	-15,000	Closed	-$45K	–	254
2016 Q3	$45K	Sell	15,000 -20,000	-57%	-$1.41M	0.04%	219
2016 Q2	$39K	Sell	35,000 -5,000	-13%	-$315K	0.03%	216
2016 Q1	$144K	Buy	+40,000	New	+$2.66M	0.15%	107

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FT Options's ALNY Position: Q3 2017 in Review

FT Options sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 2,938 shares — an estimated $251K sold.

FT Options first reported a position in ALNY in Q4 2016 and held it in 3 quarters. The position peaked at $247K in Q1 2017. 235 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

FT Options reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
FT Options sold 2,938 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $251K.
FT Options first reported a position in Alnylam Pharmaceuticals in Q4 2016 and held it in 3 quarters.
FT Options's Alnylam Pharmaceuticals position peaked at $247K in Q1 2017.
235 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.